Arcutis Biotherapeutics, Inc. ARQT

50-60$ EOY $ARQT

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics, Inc.
October 06, 2026 08:19 ET
Newly created award category highlights innovation in prescription skin treatment
ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

Becoming a profitable company, see you at the earnings $ARQT

$ARQT see you at 40$ :)

$ARQT Over the past 90 days, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 35.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ARQT has gained about 202.5% so far this year. At the same time, Medical stocks have gained an average of 5.6%. This means that Arcutis Biotherapeutics, Inc. is outperforming the sector as a whole this year.

$ARQT ARQT Sales Forecast
Next quarter’s sales forecast for ARQT is $36.36M with a range of $35.70M to $38.00M. The previous quarter’s sales results were $30.86M. ARQT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.76% of the time in the same period. In the last calendar year ARQT has Outperformed its overall industry.

$ARQT ARQT Earnings Forecast
Next quarter’s earnings estimate for ARQT is -$0.41 with a range of -$0.44 to -$0.38. The previous quarter’s EPS was -$0.42. ARQT beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARQT has Outperformed its overall industry.

$ARQT Waste time on you? Nah

$ARQT Taking into account the latest results, the most recent consensus for Arcutis Biotherapeutics from six analysts is for revenues of US$166.5m in 2024. If met, it would imply a substantial 26% increase on its revenue over the past 12 months. Losses are supposed to decline, shrinking 12% from last year to US$1.49. Before this latest report, the consensus had been expecting revenues of US$164.4m and US$1.70 per share in losses. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a cut to losses per share in particular.

Zacks is reporting an earnings miss and downgraded it to hold. Wtf.